Stock Movers Eli Lilly Drug Test Result; AbbVie Beat; WBD Layoffs
Jul 31, 2025
Eli Lilly's diabetes drug Mounjaro shows promising heart health benefits but faces market skepticism. Meanwhile, AbbVie celebrates a sales boom, raising its profit forecast thanks to strong new immunology drugs. In a different realm, Warner Bros Discovery announces major layoffs, impacting about 10% of its workforce amid a strategic overhaul. Tune in for insights into these market shifts and their implications!
AI Snips
Chapters
Transcript
Episode notes
Mounjaro Matches, Not Beats Trulicity
- Eli Lilly's Mounjaro diabetes drug was as effective as the older Trulicity in preventing heart attacks and strokes.
- The market reacted negatively because Mounjaro failed to show significant superiority despite high expectations.
AbbVie Beats Earnings Expectations
- AbbVie raised its full-year profit forecast after strong sales of new immunology drugs.
- The company beat Wall Street estimates with $15.42 billion in sales and a 12% rise in adjusted earnings.
Warner Bros Discovery Layoffs
- Warner Bros Discovery will cut about 10% of its workforce across various divisions.
- This move aligns with their plan to split into two separate publicly traded companies.